Chromophil Renal Cell Carcinoma - 22 Studies Found
| Completed |
: Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma : Papillary Renal Cell Carcinoma : 2015-06-19 : Drug: axitinib Other Name: Inlyta |
| Completed |
: Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma :
|
| Completed |
: A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer : Papillary Renal Cell Carcinoma : 2013-12-20 : Drug: INC280 Supplied by Novartis as film-coated tablet for oral use. |
| Completed |
: A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) : Carcinoma, Renal Cell : 2008-07-29 : Drug: foretinib (formerly GSK1363089 or XL880) treatment with oral foretinib on one of 2 dosing regimens |
| Active, not recruiting |
: A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) : Papillary Renal Cell Cancer : 2014-04-23 : Drug: AZD6094 AZD6094 is a potent and selective small molecule cMet kinase inhibitor. |
| Active, not recruiting |
: Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery :
: |
| Terminated |
: Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer : Kidney Cancer : 2008-01-22 : Biological: bevacizumab 15 mg/kg over 90 minutes every 3 weeks |
| Terminated |
: Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer : Kidney Cancer : 2007-10-05 : Drug: sunitinib malate |
| Completed |
: Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer : Kidney Cancer : 2007-04-11 : Drug: sunitinib malate |
| Not yet recruiting |
: Savolitinib vs. Sunitinib in MET-driven PRCC :
: |